Enoxaparin Sodium Market : Size, Share, Growth, Analysis, Key Players, Revenue, | Valuates Reports

Enoxaparin Sodium Market Size
The global Enoxaparin Sodium market was valued at US$ 3315 million in 2023 and is anticipated to reach US$ 5415 million by 2030, witnessing a CAGR of 7.1% during the forecast period 2024-2030.
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-6L9458/Global_Enoxaparin_Sodium_Market_Insights_and_Forecast_to_2028

Enoxaparin Sodium Market
Enoxaparin sodium is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
The core global manufacturers of enoxaparin sodium include Sanofi, Teva, Techdow (Hepalink), Fresenius Kabi, Rovi and Amphastar. The top three manufacturers account for approximately 66% of the global share. Sanofi is the world's largest manufacturer of enoxaparin sodium, with a market share of approximately 42%.
Europe is the world's largest enoxaparin sodium market, accounting for nearly 60% of the market share. The second and third places are North America and Asia, accounting for 19% and 16% respectively.
In terms of product type, 60 mg/0.6mL occupies a dominant position, accounting for 29% of the market share. At the same time, in terms of sales channels, hospitals and clinics are the main sales channels, accounting for 80%.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Enoxaparin Sodium, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enoxaparin Sodium.
The Enoxaparin Sodium market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Enoxaparin Sodium market comprehensively. Regional market sizes, concerning products by Type, by Sales Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Enoxaparin Sodium manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Sales Channel, and by region.

Get regional report
https://reports.valuates.com/request/regional/QYRE-Auto-6L9458/Global_Enoxaparin_Sodium_Market_Insights_and_Forecast_to_2028

Segment by Type

• 20 mg/0.2mL
• 30 mg/0.3mL
• 40 mg/0.4mL
• 60 mg/0.6mL
• 80 mg/0.8mL
• 100 mg/1mL
• 120 mg/0.8mL
• 150 mg/1mL
• 300mg/3mL

Segment by Sales Channel

• Hospital & Clinic
• Pharmacy
• Others

By Company

Sanofi, Techdow (Hepalink), Teva, Nanjing King-friend, Rovi, Fresenius Kabi, Fosun Pharma(Gland Pharma), Amphastar, Sandoz (Novartis), Apotex, Huadong Medicine, Cipla, Taj Pharma, Chengdu Baiyu Pharmaceutical, Changzhou Qianhong Bio-pharma, Beijing SL Pharmaceutical
View full report
https://reports.valuates.com/market-reports/QYRE-Auto-6L9458/global-enoxaparin-sodium

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.